Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization associated with a dome-shaped macula in pathologic myopia

Response to Treatment of Choroidal Neovascularization in Highly Myopic Eyes With Dome-Shaped Macula

“…5,6,[17][18][19] However, in a large study including 1,118 highly myopic eyes, the incidence of CNV was not significantly associated with DSM, but on the contrary, it was more frequent without this anatomical feature. 4 Although several studies proved the long-term efficacy of anti-VEGF therapy in myopic CNVs, 12,20,21 only few studies analyzed the presence of DSM as a risk factor for the course of the disease. 13,22 Cai et al 13 followed a cohort of 24 myopic subjects with CNV treated with ranibizumab (6 with DSM), showing that while DSM eyes had higher BCVA at baseline, both groups were similar after 12 months.…”

“…A combination of OCT, FA, and ICGA were used for the diagnosis of CNV and classification of its type as previously described. 11,12 The CNV area was calculated using FA ± ICGA venous intermediate-late frames (5-10 minutes) or late frames (15-30 minutes) when the neovascular net was at its best visibility. The CNV was considered foveal when it involved the central millimeter (as checked through FA ± ICGA and OCT); otherwise, it was classified as extrafoveal.…”

“…4,5,9 Although the efficacy of intravitreal antivascular endothelial growth factor (VEGF) therapy was largely proved in the treatment of myopic CNV, 10,11 very few studies investigated whether the presence of DSM and other related morphological features could influence the prognosis of these patients. 12,13 In this study, we compared the clinical and visual outcomes of anti-VEGF therapy in myopic eyes with or without DSM, considering several morphological features that could affect the response to treatment.…”